NCT07213713Not yet recruiting
Evaluation of Anti-Xa Activity in Patients With Severe Obesity After Subcutaneous Injection of Enoxaparin for Antithrombotic Prophylaxis at Two Different Sites.
Source: ClinicalTrials.gov · Last updated 9 Oct 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To evaluate appropriateness of enoxaparin bioavailability at two different sites of subcutaneous administration (arms or abdomen) in primary or secondary prevention of thromboembolism in a population of patients with severe obesity
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 80 (estimated)
- First submitted
- 2 Oct 2025
- Start date
- 1 Oct 2025
- Primary completion date
- 1 Oct 2027
- Lead sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Diseases
- Obesity
- NCT number
- NCT07213713
What you commit to
- Study type: Observational
- Planned participants: 80
- From 1 Oct 2025 to the primary completion date, 1 Oct 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- bleeding within the three months prior to admission,
- concurrent administration of subcutaneous drugs (i.e. insulin, GLP-1 receptor agonists, etc.).
Other illness
- active bleeding,
- active gastroduodenal ulcer,
- severe bleeding diathesis,
- recent/planned/emergency high bleeding-risk surgery/procedure,
- acute intracranial hemorrhage,
- known hypersensitivity to enoxaparin (e.g. pruritus, urticaria, anaphylactic/anaphylactoid reactions),
- history of immune mediated heparin-induced thrombocytopenia (HIT),
- severe uncontrolled hypertension,
Lab values
- creatinine clearance \<30 mL/min (based on Cockcroft-Gault equation using adjusted body weight),
- low platelet count (\<50.000/microL or \<100.000/microL plus additional risk factors for bleeding),
Other
- pregnant women,
- major trauma,
- diabetic or hemorrhagic retinopathy,
Who the study is looking for
- BMI \>40 kg/m2
- indication to primary or secondary thromboprophylaxis (Padua Score \> 4), as clinical practice
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.